Novo Nordisk A/S Sponsored ADR Class B(NVO.US)7.2mg Semaglutide Listing Application Approved by EMA

On July 8th, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) announced that the marketing application for 7.2mg semaglutide for weight management has been accepted by the European Medicines Agency (EMA). This marketing application is based on the positive results of Phase III STEP UP study and Phase III STEP UP T2D study. The results show that patients had an average baseline weight of 113kg. By week 72 of treatment, patients in the 7.2mg semaglutide group, 2.4mg semaglutide group, and placebo group experienced weight reductions of 20.7%, 17.5%, and 2.4% respectively. Additionally, 33.2% of patients in the 7.2mg semaglutide group achieved a weight reduction of 25% or more, while this percentage was 16.7% for the 2.4mg semaglutide group and 0% for the placebo group.